搜索
强生
JNJ添加自选
259.290USD
-3.750-1.43%
收盘 07/06, 16:00（美东）报价延迟15分钟
624.00B总市值
29.67市盈率 TTM
关于 强生 公司
强生公司（Johnson & Johnson）通过旗下子公司，专注医疗健康领域产品的研发、生产与全球行销。公司聚焦提升人类健康与福祉，并分为 「Innovative Medicine（创新医药）」与「J&J MedTech（医疗科技）」 两大业务 。 Innovative Medicine 深耕免疫学、传染病、神经科学、肿瘤学、肺动脉高压、心血管和代谢疾病等治疗领域。医疗科技部门提供骨科、外科、介入治疗、心血管介入与视觉保健等产品，并因收购 Shockwave Medical 将其商用血管内碎石术 (IVL) 平台纳入，用于 CAD 与 PAD 的微创治疗 ；同时研发数据驱动的外科机器人与数位手术解决方案。
强生简介
公司代码JNJ
公司名称Johnson & Johnson
上市日期Oct 31, 2080
CEODuato (Joaquin Boix)
员工数量138100
证券类型Ordinary Share
年结日Oct 31
公司地址One Johnson & Johnson Plaza
城市NEW BRUNSWICK
上市交易所NASDAQ OMX NASDAQ Basic NYSE
国家United States of America
邮编08933
电话17325242455
网址https://www.jnj.com/
公司代码JNJ
上市日期Oct 31, 2080
CEODuato (Joaquin Boix)
强生公司高管
名称
名称/职务
职务
持股
持股变动
Mr. Joaquin Boix Duato
Mr. Joaquin Boix Duato
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
356.30K
+22.28%
Ms. Jennifer L. Taubert
Ms. Jennifer L. Taubert
Executive Vice President, Worldwide Chairman, Innovative Medicine
Executive Vice President, Worldwide Chairman, Innovative Medicine
194.45K
+8.45%
Ms. Kathryn E. Wengel
Ms. Kathryn E. Wengel
Executive Vice President, Chief Technology Officer and Risk Officer
Executive Vice President, Chief Technology Officer and Risk Officer
114.63K
--
Mr. Joseph J. Wolk
Mr. Joseph J. Wolk
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
85.01K
+0.07%
Prof. Dr. John C. Reed, M.D., Ph.D.
Prof. Dr. John C. Reed, M.D., Ph.D.
Executive Vice President - Innovative Medicine, Research and Development
Executive Vice President - Innovative Medicine, Research and Development
24.91K
+57.22%
Ms. Elizabeth (Liz) Forminard
Ms. Elizabeth (Liz) Forminard
Executive Vice President, Chief Legal Officer
Executive Vice President, Chief Legal Officer
23.57K
+45.46%
Ms. Vanessa Broadhurst
Ms. Vanessa Broadhurst
Executive Vice President - Global Corporate Affairs
Executive Vice President - Global Corporate Affairs
23.00K
-2.57%
Ms. Kristen Mulholland
Ms. Kristen Mulholland
Chief Human Resources Officer, Executive Vice President
Chief Human Resources Officer, Executive Vice President
19.83K
+28.80%
Mr. Hubert Joly
Mr. Hubert Joly
Independent Director
Independent Director
5.00K
--
Ms. Marillyn A. Hewson
Ms. Marillyn A. Hewson
Lead Independent Director
Lead Independent Director
3.00K
--
查看更多
名称
名称/职务
职务
持股
持股变动
Mr. Joaquin Boix Duato
Mr. Joaquin Boix Duato
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
356.30K
+22.28%
Ms. Jennifer L. Taubert
Ms. Jennifer L. Taubert
Executive Vice President, Worldwide Chairman, Innovative Medicine
Executive Vice President, Worldwide Chairman, Innovative Medicine
194.45K
+8.45%
Ms. Kathryn E. Wengel
Ms. Kathryn E. Wengel
Executive Vice President, Chief Technology Officer and Risk Officer
Executive Vice President, Chief Technology Officer and Risk Officer
114.63K
--
Mr. Joseph J. Wolk
Mr. Joseph J. Wolk
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
85.01K
+0.07%
Prof. Dr. John C. Reed, M.D., Ph.D.
Prof. Dr. John C. Reed, M.D., Ph.D.
Executive Vice President - Innovative Medicine, Research and Development
Executive Vice President - Innovative Medicine, Research and Development
24.91K
+57.22%
Ms. Elizabeth (Liz) Forminard
Ms. Elizabeth (Liz) Forminard
Executive Vice President, Chief Legal Officer
Executive Vice President, Chief Legal Officer
23.57K
+45.46%
常见问题
强生的前五大股东是谁？
强生 的前五大股东如下：Mr. Joaquin Boix Duato
有多少机构持有强生(JNJ)的股份？
截至2026Q1，共有6338家机构持有强生的股份，合计持有的股份价值约为1.78B，占公司总股份的73.80%。与2025Q4相比，机构持股有所增加，增幅为-65473493.00。
哪个业务部门对强生的收入贡献最大？
在2026Q1，Oncology-DARZALEX业务部门对强生的收入贡献最大，创收14.35B，占总收入的15.24%。